ImmuCell (NASDAQ:ICCC) CEO Buys $75,920.00 in Stock

ImmuCell Corporation (NASDAQ:ICCC) CEO Boekhorst Paul Francis Oliv Te acquired 8,000 shares of the stock in a transaction on Thursday, June 18th. The stock was bought at an average cost of $9.49 per share, for a total transaction of $75,920.00. Following the transaction, the chief executive officer owned 17,785 shares of the company’s stock, valued at approximately $168,779.65. This trade represents a 81.76% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

ImmuCell Price Performance

NASDAQ ICCC opened at $9.49 on Monday. The company has a market cap of $85.88 million, a PE ratio of -158.14 and a beta of 0.55. ImmuCell Corporation has a 52 week low of $4.52 and a 52 week high of $10.75. The company has a quick ratio of 2.60, a current ratio of 4.82 and a debt-to-equity ratio of 0.24. The firm’s 50-day simple moving average is $8.97 and its two-hundred day simple moving average is $7.22.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. ImmuCell had a negative return on equity of 1.88% and a negative net margin of 1.82%.The business had revenue of $10.36 million for the quarter, compared to analysts’ expectations of $5.40 million.

Institutional Trading of ImmuCell

Several hedge funds and other institutional investors have recently made changes to their positions in ICCC. Steadtrust LLC purchased a new position in shares of ImmuCell in the 3rd quarter worth $198,000. Mesirow Financial Investment Management Inc. boosted its position in shares of ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after purchasing an additional 24,303 shares during the period. Militia Capital Management LLC bought a new stake in ImmuCell during the first quarter valued at about $114,000. Geode Capital Management LLC lifted its holdings in ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock worth $500,000 after purchasing an additional 2,907 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of ImmuCell by 3.2% during the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock worth $355,000 after acquiring an additional 1,749 shares during the last quarter. Hedge funds and other institutional investors own 13.47% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

ImmuCell Company Profile

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.